Screener
Ionis Pharmaceuticals IONS Payments For Transaction Costs Related To Sale Of Future Royalties
Payments For Transaction Costs Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties.
The source filing: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2026
- Accession
- 0000874015-26-000115
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Proceeds from issuance of 1.75 percent convertible senior notes due 2028 | - | - | 575,000 |
| 1.75 percent convertible senior notes due 2028 issuance costs | - | - | (14,175) |
| Proceeds from sale of future royalties | - | - | 500,000 |
| Payments of transaction costs related to sale of future royalties | - | - | (10,434) |
| Proceeds from real estate transaction | - | - | 32,352 |
| Principal payments on mortgage debt | (175) | (167) | (160) |
| Net cash provided by financing activities | 675,840 | 478,058 | 644,082 |
| Effects of exchange rates on cash | 702 | (273) | 352 |
Item 15. Exhibits and Financial Statement Schedules
FAQ
- What is Ionis Pharmaceuticals's payments for transaction costs related to sale of future royalties?
- Ionis Pharmaceuticals (IONS) reported payments for transaction costs related to sale of future royalties of $0 in Q4 2025.
- What is the long-term trend for Ionis Pharmaceuticals's payments for transaction costs related to sale of future royalties?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's payments for transaction costs related to sale of future royalties has grown at a -100.0% compound annual growth rate (CAGR), from $10.43M to $0.
- What does payments for transaction costs related to sale of future royalties mean?
- Direct costs incurred, such as legal, advisory, and underwriting fees, associated with the execution of royalty monetization agreements. These costs are capitalized or expensed depending on the accounting treatment of the underlying financing transaction.
Ask your AI about Ionis Pharmaceuticals's payments for transaction costs related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude